Shopping Cart
- Remove All
- Your shopping cart is currently empty
Elsilimomab (B-E8) is a monoclonal antibody targeting interleukin-6 (IL-6), inhibiting DNMT3A mutant clone-induced hematopoietic stromal cell senescence, used in the study of multiple myeloma and renal cell carcinoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $189 | In Stock | |
5 mg | $629 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Elsilimomab (B-E8) is a monoclonal antibody targeting interleukin-6 (IL-6), inhibiting DNMT3A mutant clone-induced hematopoietic stromal cell senescence, used in the study of multiple myeloma and renal cell carcinoma. |
Targets&IC50 | IL-6:1.4 nM |
In vitro | Elsilimomab is an anti-interleukin-6 (IL-6) IgG1 monoclonal antibody, with a KD of 22 pmol/L and an IC50 of 1.4 nM. |
Alias | B-E8, BE8, Anti-IL-6 MAB B-E8, Anti-Human IL6 Recombinant Antibody |
Cas No. | 468715-71-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.